Trulieve Cannabis (NYSE:TRLV) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Trulieve Cannabis (NYSE:TRLV) from a buy rating to a hold rating in a research report released on Saturday morning.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Trulieve Cannabis in a report on Friday. Zacks Research upgraded shares of Trulieve Cannabis to a “hold” rating in a research note on Thursday, June 18th. Finally, Weiss Ratings initiated coverage on shares of Trulieve Cannabis in a research report on Tuesday, June 16th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $15.00.

Trulieve Cannabis Trading Down 2.7%

Shares of NYSE:TRLV opened at $8.76 on Friday. Trulieve Cannabis has a 1 year low of $4.62 and a 1 year high of $13.28.

Trulieve Cannabis (NYSE:TRLV) last released its quarterly earnings results on Friday, August 7th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. The business had revenue of $271.00 million during the quarter, compared to analysts’ expectations of $268.82 million. On average, equities research analysts forecast that Trulieve Cannabis will post 0.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Trulieve Cannabis news, CEO Kim A. Rivers sold 136,811 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $8.76, for a total transaction of $1,198,464.36. Following the sale, the chief executive officer owned 1,476,913 shares in the company, valued at approximately $12,937,757.88. The trade was a 8.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,699,007 shares of company stock worth $14,661,355. 3.79% of the stock is currently owned by insiders.

Key Trulieve Cannabis News

Here are the key news stories impacting Trulieve Cannabis this week:

• Positive Sentiment: Trulieve reported a quarterly earnings beat. Second-quarter EPS was $0.11 versus the $0.06 analyst consensus, while revenue of $271 million modestly exceeded estimates of $268.82 million. Trulieve Reports Second Quarter 2026 Results
• Positive Sentiment: Cash flow remained a key strength. Trulieve reported a 60% gross margin, $109 million in operating cash flow and $74 million in free cash flow during the first half of 2026, which may support debt reduction, investment and financial flexibility. Trulieve Reports Second Quarter 2026 Results
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $15 price target. The target indicates substantial potential upside from the stock’s recent trading level, providing a bullish counterpoint to more cautious coverage. Cantor Fitzgerald rating update
• Neutral Sentiment: Investors are assessing several post-earnings signals. Market coverage highlights the company’s financial results, valuation and operating trends as factors likely to influence the next move in TRLV. Trulieve Cannabis Update: Key Signals to Watch
• Negative Sentiment: Wall Street Zen downgraded Trulieve to Hold. The less bullish rating may reduce near-term investor enthusiasm, particularly following the earnings release. Trulieve Cannabis Rating Lowered to Hold
• Negative Sentiment: Some analysis focused on steeper losses and weaker sales. This raises questions about the quality and sustainability of the earnings beat, despite better-than-expected reported EPS and revenue. Trulieve Reports Steeper Losses and Lower Sales

About Trulieve Cannabis

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.